The recovery meta-analysis did not find that remimazolam improved every postoperative outcome.
Twelve randomized trials involving 853 patients compared remimazolam-based anesthesia with inhalational agents. The pooled risk ratio for postoperative nausea and vomiting was 0.51, with a confidence interval of 0.27 to 0.96. Rescue antiemetic use also favored remimazolam. Pain scores, analgesic requirements, extubation time and recovery-unit stay did not clearly differ.
The analysis combined different operations and background regimens, and much of the evidence came from Korea. A pooled relative effect does not identify the absolute benefit for every baseline risk. Comparable analgesic use does not prove identical pain experience, and nausea reduction is not evidence that the benzodiazepine itself supplies clinically sufficient analgesia.
A postoperative symptom review should distinguish antiemetic treatment, opioid exposure, pain ratings and the timing of each assessment. The most favorable endpoint should not become a blanket claim of superior recovery. For case analysis, compare the actual inhalational comparator and cointerventions with the included trials. The paper supports a specific nausea-related synthesis while leaving individual pain, respiratory status and discharge readiness to their own evidence.
Source: PMC12611516, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Hepatectomy Recovery Trial Added Remimazolam and Flumazenil to a Propofol Strategy.